Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by beatsworkingon Sep 28, 2000 10:04am

234 Views

Post# 2573504

RE: Cot holding its own

You are right look at the way NT and others are getting hit. When you look at the big picture including oil and gas this one is doing just fine. Wait until the news flows and RRSP season starts. Keep the faith

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading